the doses were escalated every 4 weeks starting from 0.25 mg to 0.5 mg, 1.0 mg, and 1.7 mg until a dose of 2.4 mg was met and maintained for the remaining 16 weeks
Since the study concerns non-human subject research, consent from participants was waived and IRB approval was not required for this study
As always, any changes made to a medication regimen, including dosage adjustments, should be discussed and managed by a healthcare provider
When researchers gave semaglutide to pregnant rats at human clinical doses, they observed: Increased fetal death Structural abnormalities including abnormal heart blood vessels Changes in skeletal structures Early pregnancy losses in rabbits and cynomolgus monkeys at human-equivalent exposure levels That said, context matters
Researchers can browse Protide Healths research peptides to review documentation and third-party lab results before ordering